Staccato Loxapine Pulmonary Safety in Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The objective of this trial is to assess the pulmonary safety of 2 inhaled doses of Staccato Loxapine within a day.

Key facts

Study ID

NCT00789360

Run by

Alexza Pharmaceuticals, Inc.

People needed

30

Starts

2008-11-01

Expected to finish

2009-04-01

Last updated by the study team

2019-03-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• nonsmoker subjects in good general health with normal spirometry at screening AND baseline

You may not qualify if…

• history of asthma, COPD, or any other acute or chronic pulmonary disease or bronchodilator use

Where it is running

• Northeast Medical Research — North Dartmouth, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.